title: A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
abstract: OBJECTIVE
  Although serotonin reuptake inhibitors (SRIs) are approved for the treatment of obsessive-compulsive disorder (OCD), most OCD patients who have received an adequate SRI trial continue to have clinically significant OCD symptoms. The purpose of this study was to examine the effects of augmenting SRIs with exposure and ritual prevention, an established cognitive-behavioral therapy (CBT) for OCD.
  
  
  METHODS
  A randomized, controlled trial was conducted at two academic outpatient clinics to compare the effects of augmenting SRIs with exposure and ritual prevention versus stress management training, another form of CBT. Participants were adult outpatients (N=108) with primary OCD and a Yale-Brown Obsessive Compulsive Scale total score > or = 16 despite a therapeutic SRI dose for at least 12 weeks prior to entry. Participants received 17 sessions of CBT (either exposure and ritual prevention or stress management training) twice a week while continuing SRI pharmacotherapy.
  
  
  RESULTS
  Exposure and ritual prevention was superior to stress management training in reducing OCD symptoms. At week 8, significantly more patients receiving exposure and ritual prevention than patients receiving stress management training had a decrease in symptom severity of at least 25% (based on Yale-Brown Obsessive Compulsive Scale scores) and achieved minimal symptoms (defined as a Yale-Brown Obsessive Compulsive Scale score < or = 12).
  
  
  CONCLUSIONS
  Augmentation of SRI pharmacotherapy with exposure and ritual prevention is an effective strategy for reducing OCD symptoms. However, 17 sessions were not sufficient to help most of these patients achieve minimal symptoms.
authors.affiliation: Anxiety Disorders Clinic, New York State Psychiatric Institute, Unit 69, 1051 Riverside Dr., New York, NY 10032, USA. simpson@nyspi.cpmc
authors.forename: Helen Blair
authors.initials: HB
authors.lastname: Simpson
authors.forename: Edna B
authors.initials: EB
authors.lastname: Foa
authors.forename: Michael R
authors.initials: MR
authors.lastname: Liebowitz
authors.forename: Deborah Roth
authors.initials: DR
authors.lastname: Ledley
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Huppert
authors.forename: Shawn
authors.initials: S
authors.lastname: Cahill
authors.forename: Donna
authors.initials: D
authors.lastname: Vermes
authors.forename: Andrew B
authors.initials: AB
authors.lastname: Schmidt
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hembree
authors.forename: Martin
authors.initials: M
authors.lastname: Franklin
authors.forename: Raphael
authors.initials: R
authors.lastname: Campeas
authors.forename: Chang-Gyu
authors.initials: CG
authors.lastname: Hahn
authors.forename: Eva
authors.initials: E
authors.lastname: Petkova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002849:Chromatography, Gas; D002997:Clomipramine / Q000627:therapeutic use*; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000175:diagnosis / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D002997:Clomipramine; D017367:Selective Serotonin Reuptake Inhibitors